Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has announced the company presenting modeling data evaluating the simulated benefit and burden of established CRC ...

Exact Sciences, which is behind brands Cologuard and Oncotype DX, said it will combine CancerSEEK with its scientific platform, clinical organization, and commercial infrastructure. The company ...

quality-adjusted life-years (QALYs), and costs among patients using established screening methods of fecal immunochemical tests (FIT), colonoscopies or multitarget stool DNA test (Exact Sciences ...

“Exact Sciences is pleased to share new modeling data which demonstrates the Cologuard Plus test as an efficient CRC ... with an average of 25.5 days to return the kit; This supports mt-sDNA as an ...

“Exact Sciences is pleased to share new modeling data which demonstrates the Cologuard Plus test as an ... with an average of 25.5 days to return the kit; This supports mt-sDNA as an effective ...

Modeling data show Cologuard PlusTM test delivers highest life-years gained with fewest number of colonoscopies among noninvasive colorectal cancer (CRC) screening strategies “Exact Sciences is ...